EG382106 Inhibitors
Chemical inhibitors of the protein EG382106 function primarily through the disruption of the ubiquitin-proteasome system, which is essential for the regulated degradation of proteins within cells. These inhibitors, such as MG132, Lactacystin, Bortezomib, Carfilzomib, Ixazomib, Epoxomicin, Oprozomib, Marizomib, Delanzomib, MLN9708, and CEP-18770, have a common mechanism of action: they bind to and inhibit the catalytic activity of the proteasome. By doing so, they lead to an accumulation of ubiquitinated proteins, which are typically targeted for degradation. This accumulation results from the proteasome's inability to perform its function, which includes the degradation of proteins tagged for destruction by ubiquitin, a small protein that marks other proteins for proteasomal degradation. Since EG382106 is implicated in the ubiquitin-proteasome pathway, the inhibition of the proteasome by these chemicals results in an indirect inhibition of EG382106's function.
The action of these chemical inhibitors on the proteasome can vary. Substances like MG132, Lactacystin, and Epoxomicin are known to bind irreversibly to the proteasome, leading to long-lasting inhibition. Others, such as Bortezomib and its derivative MLN9708, as well as Carfilzomib and Ixazomib, form a reversible complex with the proteasome, offering a transitory inhibition under certain conditions. Oprozomib, being orally bioavailable, and Marizomib, with its potent irreversible binding, contribute to the sustained presence of ubiquitinated proteins within the cell. Delanzomib, targeting the chymotrypsin-like activity of the proteasome, also interferes with the proteasome's ability to process and degrade ubiquitin-tagged substrates. By preventing the normal functioning of the ubiquitin-proteasome system, these inhibitors collectively ensure that the degradation process, which EG382106 relies upon for its functional role in the cell, is compromised, leading to the inhibition of EG382106 activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 inhibits the proteasome, which is responsible for degrading ubiquitinated proteins. EG382106 is known to be involved in the ubiquitin-proteasome pathway; inhibition of the proteasome can lead to the functional inhibition of EG382106 by preventing its degradation-associated functions. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome. Since EG382106 functions in conjunction with the ubiquitin-proteasome system, the inhibition of the proteasome will increase the level of ubiquitinated proteins, thereby inhibiting the functional role of EG382106. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib functions by inhibiting the 26S proteasome. EG382106, associated with protein ubiquitination, relies on the proteasome for the degradation of its substrates. Inhibiting the proteasome with bortezomib can therefore inhibit the function of EG382106 indirectly. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib is a proteasome inhibitor. By inhibiting the proteasome, it indirectly inhibits the function of EG382106 by disrupting the degradation process of ubiquitinated proteins, which is part of the protein's functional pathway. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib targets and inhibits the 20S proteasome. As the proteasome plays a crucial role in the degradation process that EG382106 is involved in, its inhibition by ixazomib can result in the functional inhibition of EG382106. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. By inhibiting the proteasome, it indirectly inhibits EG382106 by impairing the degradation of ubiquitin-conjugated proteins, which is a key process that EG382106 is known to be involved in. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an orally bioavailable proteasome inhibitor. It inhibits the activity of the proteasome, affecting the ubiquitin-proteasome system, thereby inhibiting the function of EG382106 by disrupting its associated protein degradation pathway. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that binds to and inhibits the chymotrypsin-like activity of the proteasome. This results in an accumulation of ubiquitinated proteins, which can indirectly inhibit the function of EG382106 by disrupting its role in protein degradation. | ||||||